Physician profile
Robert R Baker
NPI 1992793293
$2,930.42
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $809 · 2021: $869 · 2022: $531 · 2023: $146 · 2024: $67.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $500.25 | 2019-2024 | Farxiga |
| Abbvie INC. | $320.30 | 2021-2022 | |
| Amgen INC. | $221.07 | 2019-2023 | Repatha, Otezla |
| Pfizer INC. | $192.09 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $179.01 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.82 | 2019-2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $154.06 | 2019-2023 | Trelegy Ellipta, Pediarix, Bexsero |
| Novo Nordisk INC | $150.22 | 2019-2022 | |
| Eisai INC. | $122.99 | 2020-2021 | |
| Lilly USA, LLC | $100.98 | 2020-2024 | Mounjaro, Taltz, Zepbound |
| Merck Sharp & Dohme LLC | $97.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.53 | 2020-2021 | |
| Mylan Specialty L.P. | $65.91 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.62 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $63.36 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $50.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.48 | 2019 | |
| Amarin Pharma, INC. | $38.34 | 2019 | |
| Abbott Laboratories | $38.21 | 2021-2024 | Freestyle Libre |
| Allergan, INC. | $35.50 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $35.12 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $28.48 | 2022 | |
| Esperion Therapeutics, INC. | $28.35 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $24.65 | 2020 | |
| Ucb, INC. | $20.14 | 2020 | |
| Exact Sciences Corporation | $16.88 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $16.83 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.64 | 2021 | |
| Astellas Pharma US INC | $14.43 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.83 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.00 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.